[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA-Cancer J Clin. 2019; 69: 7-34.
[2] Soo-Yeon, Hwang, Seojeong, Park, Youngjoo, Kwon. Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacol Ther. 2019; 199: 30-57.
[3] Burnett JC, Rossi JJ. RNA-Based Therapeutics: Current Progress and Future Prospects. Chem Biol. 2012; 19: 60-71.
[4] Sullenger BA, Nair S. From the RNA world to the clinic. Science. 2016; 352: 1417-20.
[5] Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009; 10: 155-9.
[6] Reiche K, Kasack K, Schreiber S, Lüders T, Due EU, Naume B, Riis M, Kristensen VN, Horn F, Børresen-Dale AL. Long Non-Coding RNAs Differentially Expressed between Normal versus Primary Breast Tumor Tissues Disclose Converse Changes to Breast Cancer-Related Protein-Coding Genes. Plos One. 2014; 9: e106076.
[7] Chun-Ni F, Lei M, Ning L. Comprehensive analysis of novel three-long noncoding RNA signatures as a diagnostic and prognostic biomarkers of human triple-negative breast cancer. J Cell Biochem. 2018; 120: 3185-96.
[8] Ji D, Zhong X, Jiang X, Leng K, Xu Y, Li Z, Huang L, Li J, Cui Y. The role of long non-coding RNA AFAP1-AS1 in human malignant tumors. Pathol Res Pract. 2018; 214: 1524-31.
[9] Ye Y, Chen J, Zhou Y, Fu Z, Zhou Q, Wang Y, Gao W, Zheng S, Zhao X, Chen T, Chen R. High expression of AFAP1-AS1 is associated with poor survival and short-term recurrence in pancreatic ductal adenocarcinoma. J Transl Med. 2015; 13: 137.
[10] Wu W, Bhagat TD, Yang X, Song JH, Cheng Y, Agarwal R, Abraham JM, Ibrahim S, Bartenstein M, Hussain Z, Suzuki M, Yu Y, Chen W, Eng C, Greally J, Verma A, Meltzer SJ. Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology. 2013; 144: 956-66.e4.
[11] Leng X, Ding X, Wang S, Fang T, Shen W, Xia W, You R, Xu K, Yin R. Long noncoding RNA AFAP1-AS1 is upregulated in NSCLC and associated with lymph node metastasis and poor prognosis. Oncol Lett. 2018; 16: 727-32.
[12] Wang F, Ni H, Sun F, Li M, Chen L. Overexpression of lncRNA AFAP1-AS1 correlates with poor prognosis and promotes tumorigenesis in colorectal cancer. Biomed Pharmacother. 2016; 81: 152-9.
[13] Dianatpour A, Faramarzi S, Geranpayeh L, Mirfakhraie R, Motevaseli E, Ghafouri-Fard S. Expression analysis of AFAP1-AS1 and AFAP1 in breast cancer. Cancer Biomark. 2018; 22: 49-54.
[14] Ma D, Chen C, Wu J, Wang H, Wu D. Up-regulated lncRNA AFAP1-AS1 indicates a poor prognosis and promotes carcinogenesis of breast cancer. Breast cancer-Tokyo. 2019; 26: 74-83.
[15] Fan Y, Shixu L, Siyang D, Yehuan L, Ouchen W, Xiaohua Z. Expression profile analysis of long noncoding RNA in HER-2-enriched subtype breast cancer by next-generation sequencing and bioinformatics. OncoTargets Ther. 2016; 9: 761-72.
[16] Xi Y, Shi J, Li W, Tanaka K, Dent SYR. Histone modification profiling in breast cancer cell lines highlights commonalities and differences among subtypes. BMC Genomics. 2018; 19: 150.
[17] Cai B, Wang X, Bu Qa, Li P, Xue Q, Zhang J, Ding P, Sun D. LncRNA AFAP1-AS1 Knockdown Represses Cell Proliferation, Migration, and Induced Apoptosis in Breast Cancer by Downregulating SEPT2 Via Sponging miR-497-5p. Cancer Biotherapy and Radiopharmaceuticals. 2020: Epub.
[18] Rodrigues de Bastos D, Nagai MA. In silico analyses identify lncRNAs: WDFY3-AS2, BDNF-AS and AFAP1-AS1 as potential prognostic factors for patients with triple-negative breast tumors. Plos One. 2020; 15: e0232284.
[19] Zhang K, Liu P, Tang H, Xie X, Kong Y, Song C, Qiu X, Xiao X. AFAP1-AS1 Promotes Epithelial-Mesenchymal Transition and Tumorigenesis Through Wnt/β-Catenin Signaling Pathway in Triple-Negative Breast Cancer. Front Pharmacol. 2018; 9: 1248.
[20] Zhang X, Zhou Y, Mao F, Lin Y, Shen S, Sun Q. lncRNA AFAP1-AS1 promotes triple negative breast cancer cell proliferation and invasion via targeting miR-145 to regulate MTH1 expression. Sci Rep. 2020; 10: 7662.
[21] Zhenze, Zhao, Veronica, Partridge, Michaela, Sousares, Spencer, Shelton, Cory. microRNA-2110 functions as an onco-suppressor in neuroblastoma by directly targeting Tsukushi. Plos One. 2018; 13: e0208777.
[22] Wang ZY, Hu M, Dai M-h, Xiong J, Zhang S, Wu H-j, Zhang S-s, Gong Z-j. Upregulation of the long non-coding RNA AFAP1-AS1 affects the proliferation, invasion and survival of tongue squamous cell carcinoma via the Wnt/β-catenin signaling pathway. Mol Cancer. 2018; 17: 3.
[23] Guo JQ, Li S-j, Guo G-x. Long Noncoding RNA AFAP1-AS1 Promotes Cell Proliferation and Apoptosis of Gastric Cancer Cells via PTEN/p-AKT Pathway. Dig Dis Sci. 2017; 62: 2004-10.
[24] Hong-lei, Luo, Ming-de, Huang, Jia-ni, Guo, Rui-hua, Fan, Xiao-tian, Xia. AFAP1-AS1 is upregulated and promotes esophageal squamous cell carcinoma cell proliferation and inhibits cell apoptosis. Cancer Med. 2016; 5: 2879-85.
[25] Wu W, Bhagat TD, Yang X, Song JH, Cheng Y, Agarwal R, Abraham JM, Ibrahim S, Bartenstein M, Hussain Z. Hypomethylation of Noncoding DNA Regions and Overexpression of the Long Noncoding RNA, AFAP1-AS1, in Barrett\"s Esophagus and Esophageal Adenocarcinoma. Gastroenterology. 2013; 144: 956-66.e4.
[26] Zhao Z, Partridge V, Sousares M, Shelton SD, Holland CL, Pertsemlidis A, Du L. microRNA-2110 functions as an onco-suppressor in neuroblastoma by directly targeting Tsukushi. Plos One. 2018; 13: e0208777.
[27] Kim JY, Jung HH, Ahn S, Bae S, Lee SK, Kim SW, Lee JE, Nam SJ, Ahn JS, Im Y-H. The relationship between nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment. Sci Rep. 2016; 6: 31804.
[28] Safe S, Imanirad P, Sreevalsan S, Nair V, Jutooru I. Transcription factor Sp1, also known as specificity protein 1 as a therapeutic target. Expert Opin Ther Targets. 2014; 18: 759-69.
[29] Zhao Y, Ma J, Fan Y, Wang Z, Tian R, Ji W, Zhang F, Niu R. TGF-β transactivates EGFR and facilitates breast cancer migration and invasion through canonical Smad3 and ERK/Sp1 signaling pathways. Mol Oncol. 2018; 12: 305-21.
[30] Monteleone E, Orecchia V, Corrieri P, Schiavone D, Avalle L, Moiso E, Savino A, Molineris I, Provero P, Poli V. SP1 and STAT3 Functionally Synergize to Induce the RhoU Small GTPase and a Subclass of Non-canonical WNT Responsive Genes Correlating with Poor Prognosis in Breast Cancer. Cancers. 2019; 11: 101.
[31] Sheng L, Wu J, Gong X, Dong D, Sun X. SP1-induced upregulation of lncRNA PANDAR predicts adverse phenotypes in retinoblastoma and regulates cell growth and apoptosis in vitro and in vivo. Gene. 2018; 668: 140-5.
[32] Xu Y, Yao Y, Jiang X, Zhong X, Wang Z, Li C, Kang P, Leng K, Ji D, Li Z. SP1-induced upregulation of lncRNA SPRY4-IT1 exerts oncogenic properties by scaffolding EZH2/LSD1/DNMT1 and sponging miR-101-3p in cholangiocarcinoma. J Exp Clin Cancer Res. 2018; 37: 81.
[33] Ma X, Miao H, Jing B, Pan Q, Zhang H, Chen Y, Zhang D, Liang Z, Wen Z, Li M. Claudin-4 controls the proliferation, apoptosis, migration and in vivo growth of MCF-7 breast cancer cells. Oncol Rep. 2015; 34: 681-90.
[34] Lanigan F, McKiernan E, Brennan DJ, Hegarty S, Millikan RC, McBryan J, Jirstrom K, Landberg G, Martin F, Duffy MJ, Gallagher WM. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer. Int J Cancer. 2009; 124: 2088-97.
[35] Bondy-Chorney E, Baldwin RM, Didillon A, Chabot B, Jasmin BJ, Côté J. RNA binding protein RALY promotes Protein Arginine Methyltransferase 1 alternatively spliced isoform v2 relative expression and metastatic potential in breast cancer cells. Int J Biochem Cell Biol. 2017; 91: 124-35.
[36] Zhang X, Zhao Y, Wang C, Ju H, Liu W, Zhang X, Miao S, Wang L, Sun Q, Song W. Rhomboid domain-containing protein 1 promotes breast cancer progression by regulating the p-Akt and CDK2 levels. Cell Commun Signal. 2018; 16: 65.
[37] Huang C, Ji X, Peng Y, Wu M, Wu W, Luo Y, Cheng G, Zhu Y. Silencing of rhomboid domain containing 1 to inhibit the metastasis of human breast cancer cells in vitro. Iran J Basic Med Sci. 2018; 21: 1161-6.
[38] Holland DG, Burleigh A, Git A, Goldgraben MA, Perez-Mancera PA, Chin SF, Hurtado A, Bruna A, Ali HR, Greenwood W, Dunning MJ, Samarajiwa S, Menon S, Rueda OM, Lynch AG, McKinney S, Ellis IO, Eaves CJ, Carroll JS, Curtis C, Aparicio S, Caldas C. ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol Med. 2011; 3: 167-80.